Vol 90, No 1 (2019)
Research paper
Published online: 2019-01-31

open access

Page views 2318
Article views/downloads 1580
Get Citation

Connect on Social Media

Connect on Social Media

Peroxiredoxin-5 is a negative survival predictor in ovarian cancer

Jacek Sienko1, Pawel Gaj2, Krzysztof Czajkowski1, Dominika Nowis345
Pubmed: 30756364
Ginekol Pol 2019;90(1):1-6.


Objectives: Peroxiredoxins (PRDXs) constitute a family of antioxidant enzymes which are also involved in the process of carcinogenesis. They are composed of six identified isoforms (PRDX-1-6) and are supposed to play different roles in tumor progression, depending on type of cancer and member of the PRDX family. The aim of the study was to assess the prog- nostic value of PRDXs in ovarian cancer. Material and methods: a dataset of patients with ovarian cancer from The Cancer Genome Atlas was analyzed. Expression of PRDX-1 to 6 mRNA was evaluated in 260 samples. The prognostic value of PRDXs was assessed using the Cox regression model which included the following clinical and pathological data: age, clinical stage, tumor grade, and residual disease. Results: Within the PRDXs family, only higher expression of PRDX-5 was associated with worse overall survival both, in unselected patients and > 50-year-olds. PRDX-5 expression and residual disease were independent negative prognostic factors of patient survival. Conclusions: PRDX-5 is a negative predictor of survival in ovarian cancer.  

Article available in PDF format

View PDF Download PDF file


  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1): 7–30.
  2. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018; 319(6): 595–606.
  3. Coleman MP, Forman D, Bryant H, et al. ICBP Module 1 Working Group. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet. 2011; 377(9760): 127–138.
  4. Balmaña J, Tung NM, Isakoff SJ, et al. Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Ann Oncol. 2014; 25(8): 1656–1663.
  5. Wood ZA, Schröder E, Robin Harris J, et al. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003; 28(1): 32–40.
  6. Jin DY, Chae HZ, Rhee SG, et al. Regulatory role for a novel human thioredoxin peroxidase in NF-kappaB activation. J Biol Chem. 1997; 272(49): 30952–30961.
  7. Nicolussi A, D'Inzeo S, Capalbo C, et al. The role of peroxiredoxins in cancer. Mol Clin Oncol. 2017; 6(2): 139–153.
  8. Park MiH, Jo M, Kim YuRi, et al. Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases. Pharmacol Ther. 2016; 163: 1–23.
  9. O'Leary PC, Terrile M, Bajor M, et al. Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer. Breast Cancer Res. 2014; 16(4): R79.
  10. Lee DJ, Kang DH, Choi M, et al. Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/β-Catenin complexes in adherens junctions. Cancer Res. 2013; 73(15): 4744–4757.
  11. Choi JH, Kim TN, Kim S, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002; 22(6A): 3331–3335.
  12. Karihtala P, Mäntyniemi A, Kang SW, et al. Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003; 9(9): 3418–3424.
  13. Kim YS, Lee HL, Lee KiB, et al. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med. 2011; 26(3): 304–313.
  14. Ummanni R, Barreto F, Venz S, et al. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro. J Proteome Res. 2012; 11(4): 2452–2466.
  15. Hu JX, Gao Q, Li L. Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer. Biomed Rep. 2013; 1(2): 228–230.
  16. Pritchard C, Mecham B, Dumpit R, et al. Conserved gene expression programs integrate mammalian prostate development and tumorigenesis. Cancer Res. 2009; 69(5): 1739–1747.
  17. Chang KP, Yu JS, Chien KY, et al. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res. 2011; 10(11): 4935–4947.
  18. Karihtala P, Kauppila S, Soini Y, et al. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas. BMC Cancer. 2011; 11: 262.
  19. Jiang H, Wu L, Mishra M, et al. Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy. Am J Cancer Res. 2014; 4(5): 445–460.
  20. Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, et al. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology. 2014; 65(3): 319–327.
  21. Kinnula VL, Lehtonen S, Sormunen R, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002; 196(3): 316–323.
  22. Karihtala P, Mäntyniemi A, Kang SW, et al. Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003; 9(9): 3418–3424.
  23. Pylväs M, Puistola U, Kauppila S, et al. Oxidative stress-induced antioxidant enzyme expression is an early phenomenon in ovarian carcinogenesis. Eur J Cancer. 2010; 46(9): 1661–1667.
  24. Gérard AC, Many MC, Daumerie Ch, et al. Peroxiredoxin 5 expression in the human thyroid gland. Thyroid. 2005; 15(3): 205–209.
  25. Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007; 9(6): R76.
  26. Raatikainen S, Aaaltomaa S, Kärjä V, et al. Increased Peroxiredoxin 6 Expression Predicts Biochemical Recurrence in Prostate Cancer Patients After Radical Prostatectomy. Anticancer Res. 2015; 35(12): 6465–6470.
  27. Zhu H, Santo A, Li Y. The antioxidant enzyme peroxiredoxin and its protective role in neurological disorders. Exp Biol Med (Maywood). 2012; 237(2): 143–149.
  28. Nguyên-Nhu NT, Berck J, Clippe A, et al. Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA. Biochim Biophys Acta. 2007; 1769(7-8): 472–483.
  29. Graves JA, Metukuri M, Scott D, et al. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem. 2009; 284(10): 6520–6529.
  30. Kim B, Kim YS, Ahn HM, et al. Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. Int J Oncol. 2017; 51(1): 298–306.
  31. Byun JMi, Kim SuS, Kim KiT, et al. Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 2018; 15(4): 5111–5118.
  32. Karihtala P, Soini Y, Vaskivuo L, et al. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer. 2009; 19(6): 1047–1051.
  33. Kotsopoulos J, Gronwald J, Karlan B, et al. Hereditary Ovarian Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group, Hereditary Breast Cancer Clinical Study Group. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat. 2014; 143(3): 579–586.
  34. Fernandez-Ranvier GG, Weng J, Yeh RF, et al. Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13. World J Surg. 2008; 32(5): 873–881.
  35. Chung KH, Lee DH, Kim Y, et al. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma. J Proteome Res. 2010; 9(1): 451–457.
  36. Li XQ, Zhang SL, Cai Z, et al. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett. 2009; 275(1): 109–116.
  37. Duan J, Lang Y, Song C, et al. siRNA targeting of PRDX3 enhances cisplatin‑induced apoptosis in ovarian cancer cells through the suppression of the NF‑κB signaling pathway. Mol Med Rep. 2013; 7(5): 1688–1694.
  38. Wang Xy, Wang Hj, Li Xq. Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer. Tumour Biol. 2013; 34(4): 2275–2281.